Objective: We observed that two osteosarcoma cell lines from the same tumor displayed marked differences in their sensitivities to photodynamic therapy (PDT) with aminolevulinic acid hexyl ester (hALA-PDT). We investigated why these two closely related lines had different hALA-PDT sensitivities and whether the PDT phototoxicity of the less sensitive cell line could be increased by a simultaneous application of hyperthermia (HT). Methods: Flow cytometry was used to evaluate the intracellular accumulation of protoporphyrin IX (PpIX), a metabolic product of aminolevulinic acid, in two human mandibular osteosarcoma cell lines (HOSM-1 and HOSM-2) treated with HT, hALA-PDT, or hALA-PDT combined with HT (PDT + HT). With hALA-PDT, cells treated with 0.2 mM hALA were irradiated with a light dose of 10–80 J/cm2 from a near-infrared irradiator. With PDT + HT, the cells were treated as for hALA-PDT except that the temperature was raised to 43.5°C during irradiation. Results: At 6 h after hALA treatment, HOSM-2 cells carried about 1.53-fold more PpIX than HOSM-1 cells. With hALA-PDT, the survival rate for HOSM-1 cells treated with 80 J/cm2 irradiation was 35.7%, while that for HOSM-2 cells treated with 40–80 J/cm2 was below 12%. With PDT + HT, the survival rate for HOSM-1 and HOSM-2 cells treated with 80 J/cm2 irradiation was 14.1% and 10.7%, respectively. Conclusion: A combination therapy comprising hALA-PDT + HT treatment may be very useful for the treatment of tumors containing cells that are insensitive to hALA-PDT, such as the HOSM-1 cell line described in this study.
Get full access to this article
View all access options for this article.
References
1.
MorganJ., OseroffA.R.2001. Mitochondria-based photodynamic anti-cancer therapy. Adv. Drug Deliv., 49:71–86.
2.
DoughertyT.J.2002. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg., 20:3–7.
3.
SchweitzerV.G.1990. Photodynamic therapy for treatment of head and neck cancer. Otolaryngol. Head Neck Surg., 102:225–232.
4.
ManivasagerV., HengP.W., HaoJ., ZhengW., SooK.C., OlivoM.2003. A study of 5-aminolevulinic acid and its methyl ester used in in vitro and in vivo systems of human bladder cancer. Int. J. Oncol., 22:313–318.
5.
PengQ., WarloeT., BergK.et al.1997. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer, 79:2282–2308.
6.
XuS., WangX., XuW., XiaY., ZhangC.2002. Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin. Med. J. (Engl.), 115:1141–1145.
7.
de BloisA.W., ThissenM.R., de BruijnH.S.et al.2001. In vivo pharmacokinetics of protoporphyrin IX accumulation following intracutaneous injection of 5-aminolevulinic acid. J. Photochem. Photobiol. B., 61:21–29.
8.
HarmonB.V., CorderA.M., CollinsR.J.et al.1990. Cell death induced in a murine mastocytoma by 42–47 degrees C heating in vitro: evidence that the form of death changes from apoptosis to necrosis above a critical heat load. Int. J. Radiat. Biol., 58:845–858.
9.
RemaniP., OstapenkoV.V., AkagiK., BhattathiriV.N., NairM.K., TanakaY.1999. Relation of transmembrane potential to cell survival following hyperthermia in HeLa cells. Cancer Lett., 144:117–123.
10.
YuenW.F., FungK.P., LeeC.Y.et al.2000. Hyperthermia and tumour necrosis factor-alpha induced apoptosis via mitochondrial damage. Life Sci., 67:725–732.
11.
DeweyW.C., HopwoodL.E., SaparetoS.A., GerweckL.E.1977. Cellular responses to combinations of hyperthermia and radiation. Radiology, 123:463–474.
12.
YanaseS., NomuraJ., MatsumuraY.et al.2006. Synergistic interaction of 5-aminolevulinic acid-based photodynamic therapy with simultaneous hyperthermia in an osteosarcoma tumor model. Int. J. Oncol., 27:365–373.
13.
RodriguezL., BatlleA., VenosaG.et al.2006. Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells. Br. J. Pharmacol., 147:825–833.
14.
YanaseS., NomuraJ., MatsumuraY.et al.2005. Enhancement of the effect of 5-aminolevulinic acid-based photodynamic therapy by simultaneous hyperthermia. Int. J. Oncol., 27:193–201.
15.
TagawaT., NomuraJ., KihiraH., MurataM.1989. A newly established osteosarcoma cell line from mandible. Mie Med. J., 39:279–286.
16.
NaritaM., NomuraJ., NakaseM.et al.2004. Characterization of the human mandibular osteoblastic osteosarcoma cell line HOSM-2 after long-term culture. Oral Oncol., 40:742–750.
17.
SeidlJ., RauchJ., KriegR.C., AppelS., BaumgartnerR., KnuechelR.2001. Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer. Int. J. Cancer, 92:671–677.
18.
ValerioteF., LinH.1975. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother. Rep., 59:895–900.
19.
NomuraJ., YanaseS., TokudaT.et al.2006. Griseofulvin enhances the effect of aminolevulinic acid-based photodynamic therapy in vitro. Photomed. Laser Surg., 24:186–191.
20.
TsaiT., HongR.L., TsaiJ.C., LouP.J., LingI.F., ChenC.T.2004. Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells. Lasers Surg. Med., 34:62–72.
21.
JiZ., YangG., VasovicV.et al.2006. Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. J. Photochem. Photobiol. B., 84:213–220.
22.
PengQ., MoanJ., NeslandJ.M.1996. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol., 20:109–129.
23.
LuksieneZ., EggenI., MoanJ., NeslandJ.M., PengQ.2001. Evaluation of protoporphyrin IX production, phototoxicity and cell death pathway induced by hexylester of 5-aminolevulinic acid in Reh and HPB-ALL cells. Cancer Lett., 169:33–39.
24.
GrebenovaD., KuzelovaK., SmetanaK.et al.2003. Mitochondrial and endoplasmic reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. J. Photochem. Photobiol. B., 69:71–85.
25.
YowC.M., WongC.K., HuangZ., HoR.J.2007. Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell. Liver Int., 27:201–208.
26.
KuzelováK., GrebenováD., PluskalováM., MarinovI., HrkalZ.2004. Early apoptotic features of K562 cell death induced by 5-aminolaevulinic acid-based photodynamic therapy. J. Photochem. Photobiol. B., 73:67–78.
27.
SamaliA., CaiJ., ZhivotovskyB., JonesD.P., OrreniusS.1999. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J., 18:2040–2048.
28.
RaschM.H., TijssenK., VanSteveninckJ., DubbelmanT.M.1996. Synergistic interaction of photodynamic treatment with the sensitizer aluminum phthalocyanine and hyperthermia on loss of clonogenicity of CHO cells. Photochem. Photobiol., 64:586–593.
29.
ChenB., XuY., AgostinisP., De WitteP.A.2001. Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells. Int. J. Oncol., 18:1279–1285.
